|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/427 | (2006.01) |
| A61K 31/519 | (2006.01) | ||
| A61K 31/4985 | (2006.01) | ||
| A61P 5/38 | (2006.01) |
| (11) | Number of the document | 3096756 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15702917.4 |
| Date of filing the European patent application | 2015-01-21 | |
| (97) | Date of publication of the European application | 2016-11-30 |
| (45) | Date of publication and mention of the grant of the patent | 2024-06-12 |
| (46) | Date of publication of the claims translation | 2024-08-26 |
| (86) | Number | PCT/US2015/012315 |
| Date | 2015-01-21 |
| (87) | Number | WO 2015/112642 |
| Date | 2015-07-30 |
| (30) | Number | Date | Country code |
| 201461929941 P | 2014-01-21 | US | |
| 201461981033 P | 2014-04-17 | US | |
| 201462069155 P | 2014-10-27 | US |
| (72) |
GRIGORIADIS, Dimitri, E. , US
|
| (73) |
NEUROCRINE BIOSCIENCES, INC. ,
12790 El Camino Real, San Diego, CA 92130-1102,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | CRF1 receptoriaus antagonistai, skirti įgimtos antinksčių hiperplazijos gydymui |
| CRF1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA |
| Payment date | Validity (years) | Amount | |
| 2024-12-31 | 11 | 289.00 EUR |
| 2026-01-21 |